Objective: Preterm babies are prone to experiencing apnea of prematurity (AOP), mostly characterised by a pause in breathing lasting a minimum of 20 seconds. Recent literature supported higher maintenance doses of caffeine, indicating benefits. This study evaluated the cost-effectiveness of high maintenance dose (HD) versus low maintenance dose (LD) caffeine for AOP in neonates.
Methods: From the hospital perspective of Hamad Medical Corporation (HMC), Qatar, a cost-effectiveness decision-analytic model was constructed to follow the use of a HD maintenance caffeine of 20 mg/kg/dose versus a LD maintenance caffeine of 10 mg/kg/dose, in a simulated cohort of AOP neonates, over a therapy follow-up duration of six weeks, until neonatal intensive care (NICU) discharge. The clinical inputs were primarily literature-based, while the resource cost and utilisation were locally extracted in HMC. The cost-effectiveness outcome measure was calculated per therapy success, defined as survival with no apnea and successful extubation removal within 72 hours, with or without adverse events. One-way and multivariate sensitivity analyses were performed to confirm the robustness of the results.
Results: With 0.23 (95% CI, 0.23-0.23) enhancement in success rate, at United States dollar (US$) 3869 (95% CI, US$ 3823-3915) added infant cost, the HD caffeine was between dominant (34.8%) and cost-effective (63.7%), with an average incremental cost-effectiveness ratio of US $16,895 (95% CI, US$ 15,242-18,549) relative to LD caffeine per additional case of success. The hospitalisation contributed the most to the total infant cost, and the probability of patent ductus arteriosus was the model input that influenced the results most.
Conclusion: This is the first literature economic evaluation of caffeine for AOP. Despite increasing the cost of therapy, HD maintenance caffeine seems to be a cost-effective alternative to LD caffeine in Qatar. Our results support the recent global trends of increased use of HD caffeine for AOP in NICU.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11123466 | PMC |
| http://dx.doi.org/10.1080/20523211.2024.2345218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association of gene polymorphisms of adenosine and dopamine receptors with the response to caffeine citrate treatment in infants with apnea of prematurity: a prospective nested case-control study.
Ital J Pediatr
October 2024
Department of Neonatology, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, 361003, Fujian, China.
Article Synopsis
- The study examines how variations in adenosine and dopamine receptor genes, along with clinical factors, affect how preterm infants respond to caffeine citrate treatment for apnea of prematurity (AOP).
- It analyzed data from 221 preterm infants, identifying 160 as responders to treatment and 61 as non-responders, while genotyping 22 genetic polymorphisms to compare outcomes.
- Findings showed that non-responders had higher rates of complications and specific genetic variations linked to poor response, while greater gestational age was identified as a protective factor; a predictive nomogram for treatment response was also developed.
Caffeine: The Story beyond Oxygen-Induced Lung and Brain Injury in Neonatal Animal Models-A Narrative Review.
Antioxidants (Basel)
September 2024
Department of Neonatology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Article Synopsis
- * Its antioxidant properties have been shown to have protective effects on brain and lung development in preterm infants, supported by various experimental studies.
- * However, caffeine can also have negative effects when used outside of models involving oxidative stress, and its use should be carefully evaluated, especially beyond the recommended gestational age.
A landscape evaluation of caffeine citrate availability and use in newborn care across five low- and middle-income countries.
PLOS Glob Public Health
July 2024
Clinton Health Access Initiative, Boston, Massachusetts, United States of America.
Apnoea of prematurity (AOP) is a common complication among preterm infants (< 37 weeks gestation), globally. However, access to caffeine citrate (CC) that is a proven safe and effective treatment in high-income countries is largely unavailable in low- and-middle income countries, where most preterm infants are born. Therefore, the overall aim of this study was to describe the demand, policies, and supply factors affecting the availability and clinical use of CC in LMICs.
View Article and Find Full Text PDFCaffeine Abstinence in Habituated Users: Cardiovascular Responses to Exercise With Blood Flow Restriction.
J Sport Rehabil
August 2024
Applied Human Health and Physical Function Laboratory, Department of Health, Exercise Science, and Recreation Management, University of Mississippi, University, MS, USA.
Context: Blood flow restriction resistance exercise studies often require caffeine abstinence to avoid cardiovascular effects that could change the blood flow restriction stimulus. However, effects may be attenuated for habituated users.
Objective: To compare cardiovascular responses to blood flow restriction resistance exercise when habituated users consume or abstain from caffeine.
A cost-effectiveness analysis for high versus standard (low) dose caffeine for the treatment of apnea in neonatal intensive care unit.
J Pharm Policy Pract
May 2024
College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
Objective: Preterm babies are prone to experiencing apnea of prematurity (AOP), mostly characterised by a pause in breathing lasting a minimum of 20 seconds. Recent literature supported higher maintenance doses of caffeine, indicating benefits. This study evaluated the cost-effectiveness of high maintenance dose (HD) versus low maintenance dose (LD) caffeine for AOP in neonates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!